TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)
Brief Summary: Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive \[NR\]).


Options:
A: Arm Label: VX-661/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-661 plus ivacaftor combination, Drug: Ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (matched to VX-661 plus ivacaftor combination), Drug: Placebo (matched to ivacaftor) | Intervention Type: DRUG; Name: VX-661 plus ivacaftor combination; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: Placebo (matched to VX-661 plus ivacaftor combination); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo (matched to ivacaftor); Assigned to Arm(s): Placebo
B: Arm Label: N91115 + Rifampin; Type: EXPERIMENTAL; Interventions: Drug: N91115, Drug: Rifampin | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): N91115 + Rifampin | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): N91115 + Rifampin
C: Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VX-661 Plus Ivacaftor Combination Placebo, Drug: Ivacaftor placebo | Arm Label: VX-661/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-661 Plus Ivacaftor Combination, Drug: Ivacaftor | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ivacaftor placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Utility of Two Patients Decision Aids About Asthma Inhaled Controller Medication Use in Adult Patients With Asthma
Brief Summary: The purpose of this study is to determine whether the use of shared decision making aids is more effective than usual care in improving asthma knowledge, lessening decisional conflict, and enhancing adherence to treatments and asthma control in adult patients with mild to severe asthma.


Options:
A: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information
B: Arm Label: Information; Type: EXPERIMENTAL; Interventions: Behavioral: Information | Arm Label: Information and Financial Assistance; Type: EXPERIMENTAL; Interventions: Behavioral: Information | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Information; Assigned to Arm(s): Information, Information and Financial Assistance
C: Arm Label: FRAX + Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX + Decision Aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FRAX estimated fracture risk; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX estimated fracture risk | Intervention Type: BEHAVIORAL; Name: FRAX + Decision Aid; Assigned to Arm(s): FRAX + Decision Aid | Intervention Type: BEHAVIORAL; Name: FRAX estimated fracture risk; Assigned to Arm(s): FRAX estimated fracture risk
D: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Utility of Two Patients Decision Aids About Asthma Inhaled Controller Medication Use in Adult Patients With Asthma
Brief Summary: The purpose of this study is to determine whether the use of shared decision making aids is more effective than usual care in improving asthma knowledge, lessening decisional conflict, and enhancing adherence to treatments and asthma control in adult patients with mild to severe asthma.


Options:
A: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids
B: Arm Label: usual primary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PELICAN Primary care; Type: EXPERIMENTAL; Interventions: Other: PELICAN Primary Care | Arm Label: usual secondary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PELICAN Secondary Care; Type: EXPERIMENTAL; Interventions: Other: PELICAN Secondary Care | Intervention Type: OTHER; Name: PELICAN Primary Care; Assigned to Arm(s): PELICAN Primary care | Intervention Type: OTHER; Name: PELICAN Secondary Care; Assigned to Arm(s): PELICAN Secondary Care
C: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
D: Arm Label: Facilitator-Led; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Traditional; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Asthma Shared Decision Making (SDM) Toolkit; Assigned to Arm(s): Facilitator-Led, Traditional

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Pathological Phenotype to Determine Optimal Management for Moderate to Severe Preschool Wheeze
Brief Summary: This is a single-centre, randomised-controlled trial, comparing management of preschool wheeze. It specifically aims to compare management of preschool wheeze using current clinical guidelines to management determined by eosinophilic inflammation and infection. Participants will be children aged 1-5 years who have recurrent wheezing and will be allocated to one of two treatment groups, either current clinical care or pathological phenotype based management. They will be asked to make 2 study visits to the Royal Brompton Hospital over the course of 4 months.


Options:
A: Arm Label: Pathological phenotype; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclometasone, Drug: Co-amoxiclav, Drug: Azithromycin | Arm Label: Clinical guidelines; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclometasone, Drug: Co-amoxiclav, Drug: Azithromycin | Intervention Type: DRUG; Name: Beclometasone; Assigned to Arm(s): Clinical guidelines, Pathological phenotype | Intervention Type: DRUG; Name: Co-amoxiclav; Assigned to Arm(s): Clinical guidelines, Pathological phenotype | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Clinical guidelines, Pathological phenotype
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: Text Messaging | Intervention Type: BEHAVIORAL; Name: Text Messaging; Assigned to Arm(s): Text Messaging
C: Arm Label: AsthmaCare intervention; Type: EXPERIMENTAL; Interventions: Other: AsthmaCare mobile health application | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma education | Intervention Type: OTHER; Name: AsthmaCare mobile health application; Assigned to Arm(s): AsthmaCare intervention | Intervention Type: OTHER; Name: Asthma education; Assigned to Arm(s): Control group
D: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: intervention group | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intervention group; Assigned to Arm(s): intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Telemonitoring on CPAP Treatment Compliance in Obstructive Sleep Apnea (OSA) Patients
Brief Summary: The purpose of this study is to compare the effectiveness of telemonitoring versus standard follow-up on CPAP treatment compliance in Obstructive Sleep Apnea Syndrome (OSAS).


Options:
A: Arm Label: Enhanced education and Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Usual follow up | Arm Label: Usual education and Usual follow up; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual education, Other: Enhanced follow up | Arm Label: Enhanced education and Usual follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Enhanced follow up | Arm Label: Usual education with Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Usual education, Other: Usual follow up | Intervention Type: OTHER; Name: Enhanced education; Assigned to Arm(s): Enhanced education and Enhanced follow up, Enhanced education and Usual follow up | Intervention Type: OTHER; Name: Usual education; Assigned to Arm(s): Usual education and Usual follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Usual follow up; Assigned to Arm(s): Enhanced education and Enhanced follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Enhanced follow up; Assigned to Arm(s): Enhanced education and Usual follow up, Usual education and Usual follow up
B: Arm Label: standard support; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: coached group; Type: EXPERIMENTAL; Interventions: Behavioral: telephone-based counselling | Intervention Type: BEHAVIORAL; Name: telephone-based counselling; Assigned to Arm(s): coached group
C: Arm Label: MCI/OSA/CPAP Adherent; Type: EXPERIMENTAL; Interventions: Behavioral: CPAP adherence intervention | Arm Label: MCI/OSA/CPAP Non-adherent; Type: EXPERIMENTAL; Interventions: Behavioral: Attention control intervention | Intervention Type: BEHAVIORAL; Name: CPAP adherence intervention; Assigned to Arm(s): MCI/OSA/CPAP Adherent | Intervention Type: BEHAVIORAL; Name: Attention control intervention; Assigned to Arm(s): MCI/OSA/CPAP Non-adherent
D: Arm Label: Standard follow up-Sleep Unit; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard follow-up | Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Other: Telemonitoring | Intervention Type: OTHER; Name: Standard follow-up; Assigned to Arm(s): Standard follow up-Sleep Unit | Intervention Type: OTHER; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Top-down Infliximab Study in Kids With Crohn's Disease
Brief Summary: The purpose of this study is to determine whether a top-down treatment approach, prescribing infliximab (IFX) and azathioprine (AZA) at diagnose, yields better outcome in comparison to the usual step-up treatment approach, starting with prednison and AZA or exclusive enteral nutrition (EEN) and AZA, in moderate-to-severe pediatric Crohn's disease (CD) patients.


Options:
A: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade
B: Arm Label: Top-down; Type: EXPERIMENTAL; Interventions: Drug: Infliximab, Drug: Azathioprine | Arm Label: Step-up; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone, Other: Exclusive enteral nutrition, Drug: Azathioprine | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Top-down | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Step-up | Intervention Type: OTHER; Name: Exclusive enteral nutrition; Assigned to Arm(s): Step-up | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Step-up, Top-down
C: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial (RCCT) to Test the Effectiveness of Narrative Exposure Therapy (NET) Versus Dialectical-Behavioral Therapy in Reducing Trauma Related Symptoms in Women Suffering From Borderline Personality Disorder (BPD) and Posttraumatic Stress Disorder (PTSD)
Brief Summary: Narrative Exposure Therapy (NET) is an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversity. Patients with Borderline Personality Disorder (BPD) often suffer from a comorbid Posttraumatic Stress Disorder (PTSD) caused by multiple traumatic events. Therapeutic aims are the reduction of PTSD-Symptoms in these patients via activation of associative neural networks related to traumatic experiences and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography. This practice enables the processing of and coping with painful memories and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. The investigators assume that using NET the reduction of PTSD symptom severity is greater compared to treatment by Dialectical-Behavioral Therapy (DBT).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: SIC + NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Arm Label: SIC + DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): SIC + NET | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): SIC + DBT | Intervention Type: BEHAVIORAL; Name: Standard Inpatient Care; Assigned to Arm(s): SIC + DBT, SIC + NET | Intervention Type: OTHER; Name: Waiting List; Assigned to Arm(s): SIC + DBT, SIC + NET

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Super-Mini Percutaneous Nephrolithotomy (SMP) Versus Retrograde Intrarenal Surgery (RIRS) for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial (IAU-01)
Brief Summary: Shock wave lithotripsy (SWL) is recommended for kidney stones \< 20 mm. However, the stone clearance of lower pole calculi after SWL is limited, thus leading to an extended indication for mini-percutaneous nephrolithotripsy (PCNL) even for stones between 10 and 20 mm in many centers. This trend is further promoted by introduction of super-mini PCNL (SMP), which is postulated to be less invasive compared to mini-PCNL due to the miniaturized instruments. However, this issue remains controversial.

On the other hand, improvements in endoscopy technology have made retrograde stone removal more attractive. This has led to an increasing use of RIRS as a primary treatment although it is recommended only as 2nd-line option by current guidelines. However, the treatment of symptomatic lower pole calculi is a challenge for RIRS because of lower clearance rates.

The purpose of this study is to evaluate the efficacy and safety of SMP and RIRS for the treatment for symptomatic lower pole calculi renal calculi measuring 10-20 mm.


Options:
A: Arm Label: 1 ESWL; Type: N/A; Interventions: N/A | Arm Label: 2 PCNL; Type: N/A; Interventions: N/A
B: Arm Label: Tamsulosin; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamsulosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: tamsulosin; Assigned to Arm(s): Tamsulosin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group 1; Type: OTHER; Interventions: Procedure: Super-Mini Percutaneous Nephrolithotomy | Arm Label: Group 2; Type: OTHER; Interventions: Procedure: Retrograde Intrarenal Surgery | Intervention Type: PROCEDURE; Name: Super-Mini Percutaneous Nephrolithotomy; Assigned to Arm(s): Group 1 | Intervention Type: PROCEDURE; Name: Retrograde Intrarenal Surgery; Assigned to Arm(s): Group 2
D: Arm Label: RIRS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde intrarenal surgery | Arm Label: PCNL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous nephrolithotomy | Intervention Type: PROCEDURE; Name: Percutaneous nephrolithotomy; Assigned to Arm(s): PCNL | Intervention Type: PROCEDURE; Name: Retrograde intrarenal surgery; Assigned to Arm(s): RIRS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Brief Summary: The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age. The primary hypotheses tested 1) the noninferiority of concomitant versus nonconcomitant vaccination with regard to Varicella zoster virus (VZV) Geometric Mean Titer (GMT) antibody responses, 2) the acceptability of geometric mean fold rise in VZV antibody response after concomitant vaccination, and 3) the noninferiority of concomitant versus nonconcomitant vaccination with regard to influenza virus strain-specific GMT antibody responses.


Options:
A: Arm Label: GSK1437173A group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: HZ/su Lot A; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot B; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot C; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine (GSK 1437173A); Assigned to Arm(s): HZ/su Lot A, HZ/su Lot B, HZ/su Lot C
C: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3
D: Arm Label: Concomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Arm Label: Nonconcomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Placebo to ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Influenza Vaccine; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination

Answer: D